Cyclacel Pharmaceuticals's EBITDA per Share for the
three
months ended in Dec. 2023 was $-6.03.
During the past 3 years, the average EBITDA Per Share Growth Rate was 12.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 34.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 43.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cyclacel Pharmaceuticals was 53.30% per year. The lowest was -27.10% per year. And the median was 27.40% per year.
Competitive Comparison
For the Biotechnology subindustry, Cyclacel Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclacel Pharmaceuticals 3-Year EBITDA Growth Rate Distribution
For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cyclacel Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cyclacel Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYCC has been successfully added to your